Cialis (tadalafil) (Lilly USA LLC) for postprostatectomy erectile dysfunction
HAYES, Inc.
Record ID 32010000928
English
Authors' objectives:
Prostate cancer is the most common cancer other than skin cancer in North American men and it is the second leading cause of cancer deaths in men. Although surgical removal of the prostate gland can cure cancer that has not spread into the body, this surgery puts patients at risk for erectile dysfunction, an inability to obtain a satisfactory penile erection. Using a specialized approach to prostate removal surgery that avoids damaging nerves can reduce the likelihood of erectile dysfunction after prostatectomy; however, this specialized surgery does not prevent all cases of postprostatectomy erectile dysfunction.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Phosphodiesterase Inhibitors
- Piperazines
- Prostatectomy
- Tadalafil
- Erectile Dysfunction
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.